Quantitative immunology protein panel built on the SomaScan® Assay platform
Abstract
The SomaScan® Assay is a highly multiplexed proteomic assay that uses SOMAmer® Reagents to detect proteins in various biological samples. The latest version of the SomaScan Assay allows researchers to profile 11,000 protein measurements in human blood. The SomaScan Assay is designed to provide protein epitope abundance measurements by reporting relative SOMAmer Reagent abundance quantified using DNA microarrays. This is common for highly multiplexed proteomic assays but different from clinical protein assays, which report protein concentrations. We set out to develop a Quantitative Immunology Protein Panel (QuIPP) built on the SomaScan 7K Assay, focused on a set of 58 immunologically-relevant cytokines, chemokines, and growth factors. Panel qualification was performed by developing calibration curves and demonstrating reproducibility for the biomarker measurements in serum samples with defined LLOQ and ULOQ acceptance criteria. Intra-run and inter-run CVs were calculated for high, medium, and low QC samples. 54 analytes met the standard curve, QC sample reproducibility, and plate edge effect acceptance criteria, with 34 analytes meeting strict parallelism acceptance criteria.
We have demonstrated the process for developing the QuIPP using SomaScan Assay as a core technology. The ability to generate quantitative results will allow the SomaScan Assay users to compare protein concentrations across datasets and further validate biomarker discoveries on the SomaScan Platform.
Authors
Evaldas Katilius1
Tracy Keeney1
Eduardo Tabacman1
Rong Liu2
Graham Yearwood2
Peter Schafer2
1Standard BioTools Inc
2Bristol Myers Squibb, Princeton, New Jersey
See the poster presented at Immunology 2024
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.